Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial

Pavord, Ian D; Holliday, Mark; Reddel, Helen K; Braithwaite, Irene; Ebmeier, Stefan; Hancox, Robert J; Harrison, Tim; Houghton, Claire; Oldfield, Karen; Papi, Alberto; Williams, Mathew; Weatherall, Mark; Beasley, Richard; Corin, Andrew; Helm, Colin; Poudel, Bhuwan; Sheahan, Davitt; Sheahan, Pamela; Bennett, Miriam; Chang, Caterina; Ellis, Hollie; Hancox, Bob; Hopping, Sandra; Tuffery, Christine; Ramsahai, James Michael; Simpson, Jodie; Wark, Peter; Aliani, Maria; Genco, Maddalena; Capozzolo, Alberto; Carone, Mauro; Maini, Elisa; Mancin, Jenny; Meriggi, Antonio; Perfetti, Luca; Cherubino, Francesca; Spanevello, Antonio; Visca, Dina; Zampogna, Elisabetta; Baggott, Christina; Beasley, Richard; Braithwaite, Irene; Eathorne, Allie; Ebmeier, Stefan; Fingleton, James; Hardy, Jo; Holliday, Mark; Houghton, Claire; Oldfield, Karen; Pilcher, Janine; Sabbagh, Donah; Semprini, Alex; Williams, Mathew; Harrison, Tim; Shaw, Karen; Mackisack, Summer; Montgomery, Barney; Autridge, Karen; Joseph, Joanna; Moon, Stella; Quinn, Dean; Millar-Coote, Dean; Reid, Jim; Bellini, Federico; Marchi, Martina; Morandi, Luca; Padovani, Marianna; Papi, Alberto; Scalet, Daniela; Borg, Katie; Connolly, Clare; Gittins, Anna; Hynes, Gareth; Jeffers, Helen; Pavord, Ian; Shrimanker, Rahul; Foxley, Gloria; Guevara-Rattray, Elyse; Milne, Stephen; Reddel, Helen; Toelle, Brett

doi:10.1016/s2213-2600(20)30053-9

All Outputs (2)

Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial (2020)
Journal Article
Heaney, L. G., Busby, J., Hanratty, C. E., Djukanovic, R., Woodcock, A., Walker, S. M., …Yang, F. (2021). Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial. Lancet Respiratory Medicine, 9(1), 57-68. https://doi.org/10.1016/s2213-2600%2820%2930397-0

Background Asthma treatment guidelines recommend increasing corticosteroid dose to control symptoms and reduce exacerbations. This approach is potentially flawed because symptomatic asthma can occur without corticosteroid responsive type-2 (T2)-driv... Read More about Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial.

Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial (2020)
Journal Article
Pavord, I. D., Holliday, M., Reddel, H. K., Braithwaite, I., Ebmeier, S., Hancox, R. J., …Toelle, B. (2020). Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial. Lancet Respiratory Medicine, 8(7), 671-680. https://doi.org/10.1016/s2213-2600%2820%2930053-9

Background Whether blood eosinophil counts and exhaled nitric oxide (FeNO) are associated with important outcomes in mild asthma is unclear. In this prespecified subgroup analysis of a previously published open-label clinical trial, we aimed to asse... Read More about Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial.